Nightly Eye Drop Tested for Night Driving Glare Improved Dim-Light Vision in One in Five Adults in Trial
A phase 3 trial of 0.75% phentolamine eye drops by Opus Genetics and Viatris showed 21% of adults with night vision issues improved on a dim-light eye chart after 15 days, compared to 3% on placebo. The drop, not yet FDA-approved for night vision, aims to reduce glare and halos. Results were published in the American Journal of Ophthalmology. A confirmatory trial is expected in 2026.
How this was made
The 30-second read
Why it matters
The data provide the first peer‑reviewed evidence of efficacy, supporting regulatory progress but indicating limited market impact until further trials.
Market read
Primary relevance to Viatris as a partner; broader relevance to ophthalmic biotech investors.
What to watch
Potential competition from existing pupil‑shrinking drops and insurance coverage uncertainties.
Background
Phase‑3 trial LYNX‑1 showed modest vision improvement; a follow‑up LYNX‑2 trial reported similar results. FDA granted Fast Track status for a different indication.
Ticker impact
Viatris is the commercial partner for the phentolamine eye drop and is mentioned in connection with the FDA Fast Track designation and upcoming regulatory milestones.
Modest upside if FDA decision is favorable, limited downside risk.
Viatris benefits from the partnership and regulatory progress, but the drug is still unapproved for night vision.
Market effects
Highlights growing interest in ophthalmic therapeutics and potential expansion of Viatris' eye‑care portfolio.
U.S. biotech and pharmaceutical markets may see modest attention.
Limited to investors tracking FDA‑regulated eye‑care drugs.
Counterpoint
The modest efficacy and lack of real‑world driving data may limit commercial upside.
Key entities
- CompanyOpus Genetics
Developer of the phentolamine eye drop.
- CompanyViatris
Commercial partner for the eye drop.
- RegulatorFDA
Granted Fast Track designation.
